Key Takeaways Revvity is developing T-SPOT A201 for high-volume latent TB testing, targeting a late-2027 launch.The platform can process up to 384 samples in eight hours with 45 seconds of hands-on time per sample.RVTY shares rose 2.4% after the announcement and gained 16.9% year to date, beating key benchmarks. Revvity, Inc. (RVTY - Free Report) recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. Targeted for launch in the second half of 2027, the platform is engineered to deliver the performance advantages of the T-SPOT.TB assay while enabling greater workflow efficiency and scalability for high-throughput testing environments.
Per management, the T-SPOT A201 automation platform marks a significant advancement in expanding access to the benefits of T-SPOT.TB testing for high-volume laboratories. The company believes the solution will provide the performance, workflow efficiency and competitive economics needed by high-volume clinical labs, reinforcing its commitment to delivering scalable automation technologies for infectious disease diagnostics.
Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares gained 2.4% at yesterday’s close. Year to date, the stock rose 16.9%, outperforming the industry’s 1.8% decline and the S&P 500’s 7.4% gain.
The development of the T-SPOT A201 platform is expected to strengthen Revvity’s infectious disease diagnostics and laboratory automation portfolio. By addressing the growing need for high-throughput latent TB testing, the company can enhance its position among large clinical laboratories while expanding opportunities within public health and diagnostic markets. Upon successful commercialization, the platform could drive broader adoption of Revvity’s automation solutions, support long-term customer relationships and contribute to sustained revenue growth.
RVTY currently has a market capitalization of $12.33 billion.
Image Source: Zacks Investment Research
More on the NewsThe T-SPOT A201 expands Revvity’s portfolio of automation solutions that simplify the T-SPOT.TB workflow without compromising clinical performance. The company already offers the FDA-approved and CE-IVD-marked Auto-Pure 2400 liquid handler for laboratories with lower testing volumes. Designed to process up to 24 samples per run, the Auto-Pure 2400 completes first-day T-SPOT.TB workflows in less than 3.5 hours with minimal user interaction while delivering low indeterminate results, high sensitivity and specificity, extended sample stability and efficient sample handling. These capabilities enable laboratories of different sizes to improve workflow efficiency while maintaining confidence in latent TB test results.
Built on the success of the Auto-Pure 2400 liquid handling platform, the T-SPOT A201 is designed to process up to 384 samples per instrument during an eight-hour shift while requiring only 45 seconds of hands-on time per sample. The platform is expected to help laboratories manage rising testing volumes driven by immigration screening, pre-treatment evaluations for immunosuppressive therapies and broader public health initiatives, while supporting timely and accurate latent TB detection.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and is expected to witness a CAGR of 5.3% through 2035.
Factors like the increasing adoption of rapid molecular and nucleic acid amplification tests, growing focus on detection of latent and drug-resistant tuberculosis, rising emphasis on automation, digital reporting and laboratory workflow efficiency and continued reliance on government funding and public health laboratory networks for TB testing programs are boosting the market’s growth.
Other NewsRevvity recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026.
Revvity announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.
RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.
Key Takeaways Revvity will launch Signals for Startups in the United States and EMEA in late July 2026.The program offers scalable software, guided onboarding and startup-friendly licensing.It unifies research data, reduces rework and supports investor readiness and long-term growth. Revvity, Inc. (RVTY - Free Report) recently announced the launch of Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research. It is scheduled to launch across the United States, Europe, the Middle East and the Africa region in late July 2026.
The program provides startup biotechs with enterprise-grade Signals software, guided onboarding, startup-friendly licensing and best-practice configurations tailored to their needs. By enabling startups to adopt robust informatics capabilities from day one, the program aims to accelerate scientific innovation and research productivity, and reduce the time required to generate value from R&D investments.
Per management, Signals for Startups is built to help emerging biotech companies to grow fast without being held back by fragmented data or workflow challenges that limit their ability to scale. The combination of startup-friendly access, guided onboarding and scalable Signals workflows enables early-stage teams to establish a solid digital foundation, accelerate discovery and prepare for investor readiness and future growth.
Likely Trend of RVTY Stock Following the NewsShares of RVTY have risen 3.8% since the announcement on Monday. Year to date, the stock has gained 14.2% against the industry’s 2.2% fall. However, the S&P 500 has risen 9.5% in the same timeframe.
Revvity’s Signals for Startups program is expected to strengthen its software business by capturing emerging biotech companies early in their lifecycle. As these startups expand, the company can benefit from higher customer retention and increased adoption of its broader Signals portfolio. The initiative also enhances its competitive position in scientific informatics, broadens its presence in the fast-growing biotech sector and creates opportunities for sustained revenue growth through long-term customer relationships.
RVTY currently has a market capitalization of $11.87 billion.
Image Source: Zacks Investment Research
More on the NewsEmerging biotech companies often face the challenge of managing complex research data while operating with limited IT, informatics and operational resources. Signals for Startups addresses these challenges by offering a ready-to-use, scalable informatics environment that allows scientists to focus on innovation rather than system setup. With built-in workflows for both small- and large-molecule research, the platform helps standardize data management, streamline collaboration and create a strong digital foundation from the outset.
The program also provides startups with an easy entry into the Revvity Signals ecosystem through bundled software licenses suited to early-stage organizations, while offering the flexibility to expand as the business grows through funding rounds and commercialization. By replacing disconnected tools and fragmented data management with a unified informatics platform, Signals for Startups helps companies reduce inefficiencies, minimize rework and support long-term research scalability.
The program builds on the broader capabilities of Revvity Signals Software, a comprehensive cloud-based scientific informatics platform that supports research from early discovery through later-stage development. Designed to promote multidisciplinary collaboration, Signals helps research teams centralize scientific data, optimize R&D workflows and accelerate innovation across pharmaceutical, biotechnology, clinical and specialty chemical applications. Trusted by over one million users worldwide, with a 97% renewal rate and used by all of the world's top 20 biopharma companies, Revvity Signals has established itself as a trusted scientific software platform.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the life science software market is predicted to be valued at $19.65 billion in 2026 and is expected to witness a CAGR of 10.7% through 2035.
Factors like the high investment in drug development and R&D by biotechnology and pharmaceutical companies to manage complex data, the need for integrated and compliant digital solutions, and urgent demand for AI-based automation in drug discovery and clinical trials to decrease time-to-market and R&D costs are boosting the market’s growth.
Other NewsRevvity recently announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.
RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Sin.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation,.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.
Key Takeaways Revvity added Signals Software to Anthropic's MCP directory, extending Signals AI beyond Signals One.Researchers can use Claude to access connected R&D data, trusted knowledge and scientific context.RVTY shares rose 1.4% after the news and are up 16.6% year to date against an industry decline. Revvity, Inc. (RVTY - Free Report) recently announced that its Signals Software business has been added to Anthropic’s directory for Model Context Protocol (MCP) connectors, extending the capabilities of Signals AI beyond the Signals One platform. Through the integration, scientists can access Signals AI and connected R&D knowledge using Claude, including Claude Science, Anthropic’s AI workbench for scientific research.
Per management, Signals AI was developed to help scientists understand connected R&D data, make decisions and take action. By joining Anthropic's MCP ecosystem, Revvity is expanding Signals AI beyond the Signals One platform, allowing researchers to pair Claude's reasoning capabilities with the governed data, ontology-based scientific context and trusted knowledge available across the Revvity Signals portfolio.
Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares gained 1.4% at yesterday’s closing. Year to date, shares of the company have climbed 16.6% against the industry’s 0.2% decline. The S&P 500 has risen 9.6% in the same timeframe.
The collaboration with Anthropic is a positive development for Revvity as it expands the accessibility and interoperability of its Signals AI ecosystem. By enabling secure access to connected R&D data through Claude, the company strengthens its position in the growing market for AI-enabled research informatics. Over the long term, the integration could drive wider adoption of Signals Software, reinforce Revvity’s innovation leadership and support long-term growth opportunities in the life sciences and research software markets.
RVTY currently has a market capitalization of $12.41 billion.
Image Source: Zacks Investment Research
More on the NewsAs artificial intelligence (AI) becomes increasingly central to scientific research, organizations face the challenge of providing AI models with trusted scientific data, context and knowledge. The Signals MCP connector addresses this need by enabling Claude to securely access information through Signals' intelligence layer, helping researchers search, interpret and act on complex R&D data using natural language.
The integration builds on Revvity’s recently introduced Signals AI native agentic framework, which embeds advanced AI capabilities throughout the Signals One platform. Signals AI delivers large language model functionality within Signals One. The Signals MCP connector extends these capabilities to scientists working in Claude, providing secure access to connected R&D data and scientific context from the Signals platform. This enables researchers to interact with organizational knowledge and experimental data through natural language while maintaining data traceability and scientific accuracy.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the AI in the life science analytics market is valued at $2.73 billion in 2026 and is expected to witness a CAGR of 10.8% through 2035.
Factors like the growing volumes of life sciences data, advancements in AI and machine learning technologies, rising adoption in drug discovery and precision medicine and increasing healthcare digitization and industry support are boosting the market’s growth.
Other NewsRevvity recently launched Signals AI, a native agentic framework embedded within the Signals One platform. Designed to help scientists navigate complex R&D environments, Signals AI enables researchers to interact with connected scientific data, knowledge and workflows using natural language.
During the first quarter of 2026, Revvity continued investing in innovation through the launch of Signals BioDesign software and the Opera Phenix OptiQ high-content screening system, reinforcing its focus on expanding long-term growth opportunities.
RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
BrightSpring Health, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2, reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, including Claude Science, Anthropic’s new AI workbench for scientific research.
As organizations increasingly adopt artificial intelligence to accelerate scientific research, the challenge is ensuring AI models have access to trusted scientific data, context and knowledge. Through the Signals MCP connector, Claude can securely access information through Signals' intelligence layer, helping researchers search, understand and act on complex R&D data using natural language.
"Signals AI was designed to help scientists transform connected R&D data into understanding, decisions and action," said Kevin Willoe, president of Revvity Signals Software. "By joining Anthropic's MCP ecosystem, we're extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude's reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering."
The integration complements the recently launched Signals AI native agentic framework, which embeds AI capabilities across the Signals One™ platform. Signals AI brings leading large language model (LLM) capabilities directly into the Signals platform, while the Signals MCP connector enables scientists who choose to work in Claude to securely access their connected R&D data and scientific context from Signals. By connecting Claude to the Revvity Signals platform, scientists can access organizational knowledge, experimental data and scientific context through natural language interactions while maintaining traceability and scientific precision.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows.
As scientific organizations generate increasing volumes of data across experiments, instruments, applications and systems, the challenge is no longer collecting information, but rather, turning that information into understanding and action. Signals AI introduces a new intelligence layer into the Signals One platform, allowing scientists to engage directly with connected R&D knowledge and dynamically recast it for any purpose. Signals AI helps researchers transform existing knowledge into the form needed to drive decisions and execution.
“The addition of the Signals AI capabilities within Revvity’s Signals One platform reflects a fundamental shift in how scientists work with R&D knowledge,” said Kevin Willoe, president of Revvity Signals Software. “For decades, scientific software has organized information into predefined applications, workflows and dashboards. The new features Signals AI introduces provide a new model where researchers can engage directly with organizational knowledge, ask questions in natural language and dynamically transform information. By combining the adaptive reasoning of modern AI with trusted scientific intelligence, Revvity’s Signals AI helps organizations accelerate insight without compromising scientific rigor.”
Grounded in structured scientific data, domain ontologies and validated scientific algorithms, Signals AI delivers traceable, scientifically relevant responses through natural language and interactive views of molecules, sequences, experimental results and connected knowledge. This helps scientists understand, validate and act in context while maintaining scientific rigor.
This integrated intelligence transforms scientific software from a system of record into a system of scientific understanding, helping researchers move from data to insight, and from insight to action, faster than ever before. Select capabilities of Signals AI are available today, with additional capabilities expected to be released and enhanced in the coming weeks.
About Revvity
At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Key Takeaways Revvity launched Signals AI, a native agentic framework embedded in its Signals One platform.RVTY shares fell 1% after the news, but the stock has outperformed its industry year to date.Signals AI lets researchers use natural language to explore data, workflows and scientific knowledge. Revvity, Inc. (RVTY - Free Report) recently announced the expansion of artificial intelligence capabilities across its Signals software business with the launch of Signals AI, a native agentic framework embedded within the Signals One platform. Designed to help scientists navigate complex R&D environments, Signals AI enables researchers to interact with connected scientific data, knowledge and workflows using natural language.
Rather than simply collecting information, Signals AI helps scientists transform large volumes of experimental, instrument, application and system-generated data into meaningful insights, informed decisions and actionable outcomes.
Per management, the addition of Signals AI to the Signals One platform represents a significant shift in how scientists interact with R&D knowledge. For many years, scientific software has organized information through predefined applications, workflows and dashboards. Signals AI introduces a new model, enabling researchers to access organizational knowledge directly, ask questions in natural language and dynamically transform information based on their needs. By combining the reasoning of modern AI with trusted scientific intelligence, management believes Signals AI can help organizations accelerate insight without compromising scientific rigor.
Likely Trend of RVTY Stock Following the NewsFollowing the announcement, RVTY shares dropped 1% at yesterday’s closing. In the year-to-date period, shares of the company gained 2.3% against the industry’s 7.8% decline. The S&P 500 has risen 8.9% in the same timeframe.
The launch of Signals AI is expected to strengthen Revvity’s position in the growing market for AI-powered scientific software and research informatics solutions. The ability to integrate natural language interactions into scientific workflows may increase adoption among research organizations seeking to improve productivity and innovation. The expansion of AI capabilities within the Signals One platform is likely to enhance Revvity’s competitive position and support the company’s long-term software growth strategy.
RVTY currently has a market capitalization of $11.16 billion.
Image Source: Zacks Investment Research
More on the NewsSignals AI acts as an intelligence layer across the Signals One ecosystem, allowing researchers to search, understand and repurpose scientific knowledge dynamically based on their specific needs. By leveraging structured scientific data, domain-specific ontologies and validated scientific algorithms, the platform delivers scientifically relevant, traceable and context-aware responses.
Scientists can explore and analyze molecules, biological sequences, experimental results and interconnected research knowledge through interactive views, helping them validate findings and maintain scientific rigor throughout the research process.
With these capabilities, Signals AI helps transform scientific software from a system of record into a system of scientific understanding, enabling researchers to move from data to insight and from insight to action more efficiently. Select Signals AI capabilities are currently available, with additional enhancements expected in the coming weeks.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the AI in the life science analytics market is valued at $2.73 billion in 2026 and is expected to witness a CAGR of 10.8% through 2035.
Factors like the growing volumes of life sciences data, advancements in AI and machine learning technologies, rising adoption in drug discovery and precision medicine and increasing healthcare digitization and industry support are boosting the market’s growth.
Other NewsIn May, Revvity exited the first quarter of 2026 with earnings and revenues surpassing estimates. Top-line performance benefited from growth in Life Sciences, driven by demand in pharma/biotech and academic/government markets, alongside strength in Diagnostics led by reproductive health testing. During the quarter, Revvity continued investing in innovation through the launch of Signals BioDesign software and the Opera Phenix OptiQ high-content screening system, reinforcing its focus on expanding long-term growth opportunities.
RVTY’s Zacks Rank & Key PicksRevvity currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Allspring Global Investments Holdings LLC increased its position in Revvity Inc. (NYSE: RVTY) by 127.0% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 1,751,612 shares of the company's stock after acquiring an additional 980,142 shares during the quarter. Allspring Global Investments Holdings
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the.
Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic pr.
Sumitomo Mitsui Trust Group Inc. trimmed its position in Revvity Inc. (NYSE:RVTY – Free Report) by 86.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,730 shares of the company’s stock after selling 235,296 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Revvity were worth $3,457,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RVTY. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the second quarter worth about $32,000. Cromwell Holdings LLC increased its position in Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc acquired a new stake in Revvity in the second quarter worth about $34,000. Headlands Technologies LLC acquired a new stake in Revvity in the second quarter worth about $49,000. Finally, Smartleaf Asset Management LLC increased its position in Revvity by 56.8% in the third quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock worth $58,000 after purchasing an additional 250 shares during the period. 86.65% of the stock is currently owned by institutional investors and hedge funds.
Revvity Price Performance Shares of RVTY opened at $94.00 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.40 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $118.30. The stock has a market cap of $10.51 billion, a P/E ratio of 45.19, a price-to-earnings-growth ratio of 1.90 and a beta of 1.13. The stock’s 50-day moving average price is $92.22 and its two-hundred day moving average price is $96.98.
Revvity (NYSE:RVTY – Get Free Report) last issued its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $772.06 million for the quarter, compared to analysts’ expectations of $759.81 million. During the same quarter last year, the business earned $1.42 earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, equities analysts predict that Revvity Inc. will post 4.94 earnings per share for the current year.
Revvity Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s payout ratio is 13.46%.
Wall Street Analyst Weigh In A number of equities analysts have issued reports on RVTY shares. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Evercore raised their target price on Revvity from $112.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Jefferies Financial Group raised their target price on Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Barclays restated an “equal weight” rating and set a $95.00 target price (down from $118.00) on shares of Revvity in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $110.17.
Check Out Our Latest Research Report on Revvity
Revvity Company Profile (Free Report)
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Featured Articles Five stocks we like better than Revvity
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBayforest Capital Ltd Boosts Stake in First Hawaiian, Inc. $FHB
NEXT HEADLINE »Sumitomo Mitsui Trust Group Inc. Decreases Stake in SPDR Portfolio S&P 400 Mid Cap ETF $SPMD
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from dis.
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.
Revvity (RVTY - Free Report) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +4.10%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.63 per share when it actually produced earnings of $1.7, delivering a surprise of +4.29%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Revvity, which belongs to the Zacks Medical Services industry, posted revenues of $711.12 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.85%. This compares to year-ago revenues of $664.76 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Revvity shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for Revvity?While Revvity has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Revvity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.28 on $742.53 million in revenues for the coming quarter and $5.39 on $2.98 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Ascend Wellness Holdings, Inc. (AAWH - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.
This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -44.4%. The consensus EPS estimate for the quarter has been revised 3.9% higher over the last 30 days to the current level.
Ascend Wellness Holdings, Inc.'s revenues are expected to be $114.2 million, down 10.8% from the year-ago quarter.
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.
A month has gone by since the last earnings report for Revvity (RVTY - Free Report) . Shares have added about 2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Revvity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong ExecutionRevvity delivered first-quarter 2026 adjusted earnings of $1.06 per share, up 5.0% year over year. The bottom line beat the Zacks Consensus Estimate of $1.02 by 3.9%. Quarterly revenues of $711.1 million increased 7.0% from the year-ago period and topped the consensus mark of $705.2 million by 0.8%.
Strong performance across the portfolio helped results beat expectations, with the company reporting 3% organic revenue growth for the quarter and pointing to improving signals in key end markets.
RVTY’s Segment Mix Keeps Momentum Broad-BasedRVTY’s growth was supported by contributions from both operating segments. Life Sciences revenues totaled $361.8 million, reflecting year-over-year expansion led by demand in pharma/biotech and academic/government markets.
Diagnostics revenues increased to $349.3 million, aided by strength in reproductive health. The company stated better diagnostic trends outside of China, which was partially offset by softer dynamics tied to its China Immunodiagnostics footprint.
Investment Spending and Product Mix Weigh on Revvity MarginsRevvity reported an adjusted operating margin of 23.6% in the quarter, down 200 basis points year over year. The company attributed the margin pressure to a combination of factors, including ongoing investments, an unfavorable product mix, and the impact of an extra week in the reporting period.
Adjusted gross margin was 59.5%, down 220 basis points from the prior-year quarter’s level. Below the operating line, adjusted net interest and other expense totaled $23 million, while the adjusted tax rate was 18.3%, aiding overall adjusted profitability despite the margin contraction.
Selling, general and administrative expenses totaled $253.9 million, up 1.7% year over year. Research and development expenses amounted to $57.9 million, up 8% from the year-ago quarter’s reported number.
RVTY’s Cash Generation Stays Strong Despite OutflowsThe company exited the first quarter of 2026 with cash and cash equivalents of $860.3 million compared with $919.9 million at the end of the prior quarter.
RVTY generated $115.2 million of net cash provided by operating activities in the quarter compared with $128.2 million in the year-ago period. After capital expenditures of $19.8 million and proceeds from capital disposals, free cash flow was reported at $115 million, with year-to-date free cash flow equal to 97% of adjusted net income.
The quarter also included meaningful shareholder returns. The company repurchased $86.5 million of common stock and paid $7.8 million in dividends. Revvity ended the period with $860.3 million in cash and cash equivalents, while long-term debt amounted to $2.63 billion.
Revvity’s China ImmunoDx Divestiture Reshapes the LensA key strategic development was the decision to divest its Immunodiagnostics business in China. Management noted that this unit accounted for roughly 6% of total company revenues in 2025 and confirmed that it has entered into a letter of intent with a prospective buyer, with a definitive agreement expected in the second quarter of 2026.
The divestiture is anticipated to be closed in 2027, subject to necessary regulatory approvals. Reflecting this transition, the company reported first-quarter results on both a reported and pro forma basis, with pro forma revenues of $686.9 million and pro forma adjusted earnings of $1.04 per share.
RVTY Updates Outlook on a Pro Forma BasisRVTY updated full-year 2026 guidance on a pro forma basis that excludes the China Immunodiagnostics business. The company expects total revenues of $2.81-$2.84 billion, implying 3-4% pro forma organic revenue growth, with foreign exchange expected to add about 0.5% and M&A contributing roughly 0.75%.
Pro forma adjusted earnings are projected in the $5.20-$5.30 per share band, supported by an expected adjusted operating margin of 28.4%. Additional assumptions include adjusted net interest expense and other of about $90 million, an adjusted tax rate near 18% and an average diluted share count of roughly 112 million.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -5.22% due to these changes.
VGM ScoresAt this time, Revvity has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Revvity has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerRevvity belongs to the Zacks Medical Services industry. Another stock from the same industry, Avantor, Inc. (AVTR - Free Report) , has gained 7.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
Avantor reported revenues of $1.58 billion in the last reported quarter, representing no change year over year. EPS of $0.17 for the same period compares with $0.23 a year ago.
For the current quarter, Avantor is expected to post earnings of $0.19 per share, indicating a change of -20.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.7% over the last 30 days.
Avantor has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
